Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rank in Stocks #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$41.14
Last synced: 2026-09-21
Market Cap
$182.76B
Change (1 day)
-7.78%
Change (1 year)
-32.24%
Country
DK
Trade Novo Nordisk A/S (NOVO-B)

Category

Earnings for Novo Nordisk A/S (NOVO-B)
Earnings in Jun 2026 TTM: $23.62B
According to Novo Nordisk A/S latest financial reports the company's current earnings are $23.62B. In 2024 the company made an earning of $17.75B, an increase over its 2023 earnings that were of $15.50B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Novo Nordisk A/S from 2000 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $23.62B 19.78%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$33.59B 42.24%
US
$25.20B 6.68%
US
$8.70B -63.17%
US
$21.39B -9.44%
CH
$5.95B -74.82%
US